dc.contributor
Institut Català de la Salut
dc.contributor
[Salvador F, Molina I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. [Lucas-Dato A] Internal Medicine Department, Hospital Vega Baja, 03314 Orihuela, Spain. [Roure S] Infectious Diseases Department, North Metropolitan International Health Unit, Germans Trias i Pujol University Hospital, PROSICS North Metropolitan, 08916 Badalona, Spain. [Arsuaga M] Tropical Medicine Unit, Infectious Diseases Department, La Paz-Carlos III University Hospital, 28046 Madrid, Spain. [Pérez-Jacoiste A] Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. [García-Rodríguez M] Infectious Diseases Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Lucas-Dato, Ana
dc.contributor.author
Roure, Silvia
dc.contributor.author
Arsuaga, Marta
dc.contributor.author
Pérez-Jacoiste, Asunción
dc.contributor.author
García-Rodríguez, Magdalena
dc.contributor.author
Molina Romero, Israel
dc.contributor.author
Salvador Velez, Fernando M
dc.date.issued
2022-03-11T13:14:36Z
dc.date.issued
2022-03-11T13:14:36Z
dc.identifier
Salvador F, Lucas-Dato A, Roure S, Arsuaga M, Pérez-Jacoiste A, García-Rodríguez M, et al. Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol. Pathogens. 2021 Jul;10(7):812.
dc.identifier
https://hdl.handle.net/11351/7149
dc.identifier
10.3390/pathogens10070812
dc.identifier
000676425400001
dc.description.abstract
Strongyloides stercoralis; Immunosupressió; Ivermectina
dc.description.abstract
Strongyloides stercoralis; Inmunosupresión; Ivermectina
dc.description.abstract
Strongyloides stercoralis; Immunosuppression; Ivermectin
dc.description.abstract
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
dc.description.abstract
The present work was supported by the 2020 Research Grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).
dc.format
application/pdf
dc.relation
Pathogens;10(7)
dc.relation
https://doi.org/10.3390/pathogens10070812
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Malalties parasitàries - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Parasitic Diseases::Helminthiasis::Nematode Infections::Secernentea Infections::Rhabditida Infections::Strongyloidiasis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::enfermedades parasitarias::helmintiasis::infecciones por nematodos::infecciones por Secernentea::infecciones por Rhabditida::estrongiloidiasis
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
